Balyasny Asset Management
BLCM

Balyasny Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Balyasny Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,008
Closed -$132K – 2247
2018
Q1 		$132K Buy
+2,008
New +$152K ﹤0.01% 1809
2017
Q4 		– Sell
-1,670
Closed -$193K – 2398
2017
Q3 		$193K Buy
+1,670
New +$176K ﹤0.01% 1717

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's BLCM Position: Q2 2018 in Review

Balyasny Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 2,008 shares — an estimated $132K sold.

Balyasny Asset Management first reported a position in BLCM in Q3 2017 and held it in 2 quarters. The position peaked at $193K in Q3 2017. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

  • Balyasny Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 2,008 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $132K.
  • Balyasny Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Balyasny Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $193K in Q3 2017.
  • 96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.